Open access · CC-BY
via OpenAlex
Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS
Helene Anna Haeberle, Harry Magunia, Peter Lang, Henning Gloeckner, Andreas Körner, Michael Koeppen, Tamam Backchoul, Nisar P. Malek, Rupert Handgretinger, Peter Rosenberger, Valbona Mirakaj
Journal of Intensive Care Medicine · 2021 · ▲ 56 citations
Abstract
BACKGROUND: The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether the infusion of mesenchymal stromal cells (MSCs) would help to improve pulmonary function and overall outcome in patients with severe COVID-19 ARDS. We offered MSC infusion as an extended indication to all critically ill COVID-19 patients with a Horovitz index <100. We treated 5 out of 23 patients with severe COVID-19 ARDS with an infusion of MSCs. One million MSCs/kg body weight was infused over 30 minutes, and the process was repeated in 3 patients twice and in 2 patients 3 times. RESULT: Four out of 5 MSC-treated patients compared to 50% of control patients (9 out of 18) received ECMO support (80%). The MSC group showed a higher Murray score on admission than control patients, reflecting more severe pulmonary compromise (3.5 ± 0.2 versus 2.8 ± 0.3). MSC infusion was safe and well tolerated. The MSC group had a significantly higher Horovitz score on discharge than the control group. Compared to controls, patients with MSC treatment showed a significantly lower Murray score upon discharge than controls. In the MSC group, 4 out of 5 patients (80%) survived to discharge and exhibited good pulmonary function, whereas only 8 out of 18 patients (45%) in the control group survived to discharge. CONCLUSION: MSC infusion is a safe treatment for COVID-19 ARDS that improves pulmonary function and overall outcome in this patient population.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1177/0885066621997365
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Haeberle, H.A., Magunia, H., Lang, P., Gloeckner, H., Körner, A., Koeppen, M., Backchoul, T., Malek, N.P., Handgretinger, R., Rosenberger, P., & Mirakaj, V. (2021). Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS. <em>Journal of Intensive Care Medicine</em>. https://doi.org/10.1177/0885066621997365
Vancouver
Haeberle HA, Magunia H, Lang P, Gloeckner H, Körner A, Koeppen M, et al. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS. Journal of Intensive Care Medicine. 2021. doi:10.1177/0885066621997365.
BibTeX
@article{helene2021Mesenc,
title = {Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS},
author = {Helene Anna Haeberle and Harry Magunia and Peter Lang and Henning Gloeckner and Andreas Körner and Michael Koeppen and Tamam Backchoul and Nisar P. Malek and Rupert Handgretinger and Peter Rosenberger and Valbona Mirakaj},
journal = {Journal of Intensive Care Medicine},
year = {2021},
doi = {10.1177/0885066621997365},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging and Disease 2020
Open access · CC-BY
Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
Journal of Hip Preservation Surgery 2017
Open access · CC-BY
Mesenchymal stem cell therapy in the treatment of hip osteoarthritis
Stem Cell Research & Therapy 2020
Open access · CC-BY
Comprehensive analysis of skeletal muscle- and bone-derived mesenchymal stem/stromal cells in patients with osteoarthritis and femoral neck fracture
Cell & Bioscience 2020
Open access · CC-BY
Treatment of spinal cord injury with mesenchymal stem cells
Gut 2011
Citation only
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease
Selcuk University 2022
Open access · US-GOV